If true that our drug affects all cells and many non-neurodegerenerative diseases ( diabetes?, cancer? viral infections?, autoimmune diseases? ) THEN MAY THE FDA ASSERT THAT ONE DRUG CANNOT BE PATENT PROTECTED?
But, sigma-1 receptors are not at all unique to neurons, nerve cells. Of course, in those cells restoration of normalized sigma-1 receptor activities restores normalized neuron functions, nerve-cell health. Hence, the ability of blarcamesine (Anavex 2-73) to profoundly treat or prevent various central nervous system (CNS) diseases. Medical science in the 21st century will be transformed.
It was not that long ago ((late 50's) that another branch of science (semiconductor physics) Made a similar leap from discrete electronic components (vacuum tubes to diodes-to integrated components-see patents) -eventually to microprocessors, all of which required new thinking but now looks like it was just pretty obvious-basic science. Well, it was not simple but we did it. The same kind of thing will happen here in CNS human systems thinking (IMO). The discrete components to full integration analogy works well enough.
Todays (one at a time medical thinking) will have to make the leap.
I've often wondered if A2-73 could help with weight loss. I believe chemical exposure(including pharmaceuticals) is a big contributing factor to the obesity epidemic.
To your point, falconer, it has already been reported from earlier studies that cardiovascular and eyesight health have both experienced improvements with 2-73.